Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Faustini SE, Hall A, Brown S, Roberts S, Hill H, Stamataki Z; (PITCH) consortium; Jenner MW, Owen RG, Pratt G, Cook G, Richter A, Drayson MT, Kaiser MF, Heaney JLJ. Faustini SE, et al. Among authors: kaiser mf. Br J Haematol. 2023 Jun;201(5):845-850. doi: 10.1111/bjh.18714. Epub 2023 Mar 9. Br J Haematol. 2023. PMID: 36895158
Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
Brioli A, Boyd KD, Kaiser MF, Pawlyn C, Wu P, Gregory WM, Owen R, Ross FM, Jackson GH, Cavo M, Davies FE, Morgan GJ. Brioli A, et al. Among authors: kaiser mf. Br J Haematol. 2013 Apr;161(2):291-4. doi: 10.1111/bjh.12218. Epub 2013 Jan 29. Br J Haematol. 2013. PMID: 23356460 Free article. Clinical Trial. No abstract available.
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.
Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Anthony Child J, Davies FE, Walker BA, Morgan GJ. Boyle EM, et al. Among authors: kaiser mf. Genes Chromosomes Cancer. 2015 Feb;54(2):91-8. doi: 10.1002/gcc.22222. Epub 2014 Oct 7. Genes Chromosomes Cancer. 2015. PMID: 25287954 Free PMC article.
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Pawlyn C, et al. Among authors: kaiser mf. Blood. 2015 Jan 29;125(5):831-40. doi: 10.1182/blood-2014-07-584268. Epub 2014 Nov 26. Blood. 2015. PMID: 25428216 Free PMC article. Clinical Trial.
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. Walker BA, et al. Among authors: kaiser mf. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997. Nat Commun. 2015. PMID: 25904160 Free PMC article.
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Walker BA, et al. Among authors: kaiser mf. J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282654 Free PMC article. Clinical Trial.
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
Brown S, Hinsley S, Ballesteros M, Bourne S, McGarry P, Sherratt D, Flanagan L, Gregory W, Cavenagh J, Owen R, Williams C, Kaiser M, Low E, Yong K; Myeloma UK Clinical Trials Network. Brown S, et al. BMC Hematol. 2016 May 17;16:14. doi: 10.1186/s12878-016-0053-9. eCollection 2016. BMC Hematol. 2016. PMID: 27190631 Free PMC article.
158 results